Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

AbbVie Asks U.S. Trade Agency to Block Humira Biosimilar

Dec. 17, 2021, 8:45 PM

AbbVie asked the U.S. International Trade Commission to block a biosimilar of its $20 billion-a-year Humira, saying Alvotech developed the generic using stolen trade secrets for the manufacturing process of the blockbuster arthritis drug.

  • AbbVie also named Teva, which has agreed to sell the Iceland-made Alvotech copy, called AVT02, in the U.S. in a deal worth more than $450 million, according to the complaint filed Friday at the agency
  • North Chicago, Illinois-based AbbVie turned to the trade agency after a federal judge in Chicago threw out a lawsuit after ruling he didn’t have jurisdiction to hear allegations that a former ...